ELEDON PHARMACEUTICALS

Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results

12 Nov 2024 16:01:00 By Nasdaq GlobeNewswire

Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference

06 Nov 2024 16:05:00 By Nasdaq GlobeNewswire

Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

29 Oct 2024 07:46:00 By Nasdaq GlobeNewswire

Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine

29 Oct 2024 07:45:00 By Nasdaq GlobeNewswire

Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference

11 Sep 2024 16:05:00 By Nasdaq GlobeNewswire

Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients

04 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results

14 Aug 2024 17:21:26 By Nasdaq GlobeNewswire

Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection

29 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism

02 Jul 2024 16:05:00 By Nasdaq GlobeNewswire

Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

03 Jun 2024 16:01:00 By Nasdaq GlobeNewswire

Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results

09 May 2024 07:30:00 By Nasdaq GlobeNewswire

Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress

09 May 2024 07:00:01 By Nasdaq GlobeNewswire

Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection

07 May 2024 07:05:00 By Nasdaq GlobeNewswire

Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement

07 May 2024 07:00:01 By Nasdaq GlobeNewswire

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results

28 Mar 2024 16:01:00 By Nasdaq GlobeNewswire

Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection

25 Mar 2024 16:56:42 By Nasdaq GlobeNewswire

Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human

21 Mar 2024 10:31:12 By Nasdaq GlobeNewswire

Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

13 Feb 2024 19:01:00 By Nasdaq GlobeNewswire

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook

04 Jan 2024 16:40:44 By Nasdaq GlobeNewswire

Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Dec 2023 18:00:00 By Nasdaq GlobeNewswire